Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Inclusion Criteria

• •Patients with newly diagnosed or recurrent glioma of World Health Organization (WHO) grade II (astrocytoma, oligodendroglioma, and/or oligoastrocytoma) will be eligible for this protocol
• •Patients must have had surgical resection at University of California, Los Angeles (UCLA), for which a separate informed consent was signed for the collection of their tumor prior to surgery
• •After surgery, a pathological diagnosis of low-grade glioma (WHO grade II) will need to be established
• •Patients must be able to read and understand the informed consent document; patients must sign the informed consent indicating that they are aware of the investigational nature of this study.
• •Patients must have a Karnofsky performance status (KPS) rating of \>= 60 prior to initiating treatment; patients may be enrolled at a KPS of \< 60 if it is felt that the patient will have adequate opportunity to recover to a KPS of \>= 60 by the initiation of treatment
• •Hemoglobin \>= 9 gm%
• •Absolute granulocyte count \>= 1,500
• •Platelet count \>= 100,000/microliter (uL)
• •Serum glutamic pyruvate transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT) =\< 2.5 times institutional normals
• •Bilirubin =\< 1.5mg%
• •Blood urea nitrogen (BUN) or creatinine =\< 1.5 times institutional normals